Loading...
Loading...
BNOX| Name | Value |
|---|---|
| Revenues | 662.7K |
| Cost of Revenue | 0.0K |
| Gross Profit | 662.7K |
| Operating Expense | 4,366.0K |
| Operating I/L | -3,704.0K |
| Other Income/Expense | 1,772.0K |
| Interest Income | 30.6K |
| Pretax | -1,931.7K |
| Income Tax Expense | 11.6K |
| Net Income/Loss | -1,943.0K |
Bionomics Limited is a clinical-stage biopharmaceutical company with a focus on developing novel drug candidates for central nervous system disorders and cancers. Their lead drug candidate, BNC210, targets social anxiety disorder and post-traumatic stress disorder. Additionally, they are developing BNC375 for cognitive impairment in Alzheimer's disease, BNC101 for cancer stem cells, and BNC105 for refractory colorectal cancer and relapsed/refractory chronic lymphocytic leukemia. The company generates revenue through the development and potential commercialization of these drug candidates, as well as through licensing agreements with partners such as Merck & Co., Inc.
